Cardiff Oncology — Third Quarter 2026 Earnings Summary

Cardiff Oncology reported a net loss of $30.4 million for the nine months ended September 30, 2026, driven by $32.0 million in operating expenses. The company's Phase 2 trial for onvansertib in first-line RAS-mutated metastatic colorectal cancer remains ongoing, with median progression-free survival not yet reached in the 30 mg onvansertib plus FOLFIRI/bev arm compared to approximately 11 months in standard-of-care arms. As of late September 2026, all patients in the 30 mg onvansertib arm have exceeded 21 months on treatment, with the longest duration surpassing 29 months. Cardiff holds approximately $33.8 million in cash and cash equivalents as of September 30, 2026, and plans to initiate a registrational Phase 3 trial in the first quarter of 2027.